

HELLP Syndrome in Pregnancy: Incidence, Pathophysiology, and Clinical Management

HELLP syndrome, a severe obstetric complication characterized by Hemolysis, Elevated Liver enzymes, and Low Platelet count, represents a critical challenge in maternal-fetal medicine. Emerging most commonly in the third trimester, this syndrome complicates 0.2% to 0.9% of all pregnancies and occurs in 4% to 24% of women with severe preeclampsia^{[1] [2] [3] [4]}. While often linked to preeclampsia, HELLP can manifest independently, with 10–20% of cases lacking typical hypertensive or proteinuric features^{[5] [6]}. Its rapid onset and potential for multisystem organ failure necessitate urgent intervention, often culminating in preterm delivery. This report synthesizes current evidence on HELLP syndrome's epidemiology, diagnostic criteria, and management strategies, offering critical insights for clinicians navigating this high-risk condition.

Etiology and Definition of HELLP Syndrome

Pathophysiological Basis

HELLP syndrome derives its acronym from three cardinal features:

1. **Hemolysis (H):** Microangiopathic destruction of red blood cells occurs due to endothelial damage and fibrin deposition in small vessels, producing schistocytes and spherocytes on peripheral blood smears^{[1] [2]}.
2. **Elevated Liver Enzymes (EL):** Hepatic ischemia from sinusoidal obstruction leads to periportal necrosis, reflected in aspartate aminotransferase (AST) levels ≥ 70 U/L and lactate dehydrogenase (LDH) > 600 U/L^{[1] [2] [6]}.
3. **Low Platelets (LP):** Platelet consumption from widespread endothelial activation results in thrombocytopenia ($< 100 \times 10^9/L$), distinguishing HELLP from gestational thrombocytopenia^{[2] [6]}.

While 70–80% of HELLP cases coexist with preeclampsia—characterized by hypertension and proteinuria—the syndrome's independent occurrence challenges its classification as merely a preeclampsia variant^{[5] [6]}. Pathogenic mechanisms center on placental dysfunction, including antiangiogenic factor release (e.g., soluble fms-like tyrosine kinase-1) and systemic inflammatory responses^{[2] [7]}.

Epidemiology and Risk Factors

Incidence in Pregnancy

Global incidence rates vary across populations:

- **General obstetric population:** 0.5–7.6 per 1,000 pregnancies (0.05–0.76%)^{[3] [4]}.
- **Preeclampsia-associated cases:** 4–24% of severe preeclampsia/eclampsia^{[1] [3] [4]}.
- **Postpartum onset:** 20–31% of HELLP diagnoses occur within 48 hours to one week post-delivery^{[1] [2]}.

Discrepancies in reported rates stem from differing diagnostic criteria. The Tennessee Classification System requires all three components (LDH >600 U/L, AST ≥70 U/L, platelets <100×10⁹/L), whereas partial HELLP (one or two features) may inflate incidence in some studies^{[2] [3]}.

Demographic and Clinical Risk Factors

Key risk modifiers include:

- **Maternal age:** Increased prevalence in women >35 years^{[4] [7]}.
- **Parity:** Multiparity elevates risk, particularly among white populations^{[5] [2]}.
- **Comorbidities:** Obesity (BMI ≥30), chronic hypertension, diabetes, and antiphospholipid syndrome^{[4] [7]}.
- **Obstetric history:** Prior HELLP confers 19–27% recurrence risk; preeclampsia in previous pregnancies increases susceptibility^{[1] [7]}.

Notably, 15–20% of HELLP cases lack antecedent hypertension or proteinuria, complicating early diagnosis^{[5] [6]}.

Clinical Presentation and Diagnostic Challenges

Symptomatology

HELLP manifests with protean symptoms, often mimicking viral illnesses:

- **Right upper quadrant/epigastric pain** (67–90% of cases) from hepatic distension^{[6] [7]}.
- **Neurologic symptoms:** Headaches (45–60%), visual disturbances (10–20%), and rarely seizures^{[5] [6]}.
- **Constitutional signs:** Nausea/vomiting (35–50%), edema (50–70%), and rapid weight gain^{[2] [4]}.

Diagnostic Workflow

1. Laboratory evaluation:

- **Hemolysis:** LDH >600 U/L, haptoglobin <25 mg/dL, indirect bilirubin ≥1.2 mg/dL^{[1] [2]}.
- **Hepatic dysfunction:** AST ≥70 U/L, alanine aminotransferase (ALT) elevation^{[2] [6]}.

- **Thrombocytopenia:** Platelets $<100 \times 10^9/L$, with nadir typically 24–48 hours postpartum^[2].

2. **Imaging:** Hepatic ultrasound or MRI to exclude hematoma/rupture in severe right upper quadrant pain^[6] ^[7].

Misdiagnosis remains common, with 20–30% of cases initially attributed to gastroenteritis, hepatitis, or thrombotic microangiopathies^[8] ^[6].

Management Strategies

Antepartum Stabilization

- **Corticosteroids:** Betamethasone (12 mg IM q24h) accelerates fetal lung maturation <34 weeks, prolonging pregnancy by 2–7 days^[1] ^[2].
- **Magnesium sulfate:** Neuroprotective for <32 -week gestations; prevents eclampsia in hypertensive cases^[6] ^[7].
- **Blood product support:** Platelet transfusion for counts $<20 \times 10^9/L$ or prior to cesarean delivery^[1] ^[2].

Delivery Timing and Mode

- **<24 weeks:** High fetal mortality (60–70%); termination often considered^[2] ^[7].
- **24–34 weeks:** Expectant management in tertiary centers with maternal/fetal surveillance^[1] ^[3].
- **≥ 34 weeks:** Immediate delivery, with vaginal preferred if cervical favorability permits^[1] ^[2].

Cesarean rates approach 80% due to non-reassuring fetal status or rapid maternal deterioration^[2] ^[6].

Maternal and Fetal Complications

Maternal Morbidity

- **Hepatic:** Subcapsular hematoma (0.9–2%), spontaneous rupture (1.5%), with 30% mortality if ruptured^[2] ^[7].
- **Hematologic:** Disseminated intravascular coagulation (DIC) in 20–40%, requiring cryoprecipitate/fresh frozen plasma^[2] ^[6].
- **Renal:** Acute kidney injury (5–15%) from glomerular endothelial damage^[7].

Perinatal Outcomes

- **Preterm birth:** 70% deliver <37 weeks; 15% <28 weeks^[2] ^[3].
- **Neonatal mortality:** 7–20%, primarily from respiratory distress syndrome and intraventricular hemorrhage^[3] ^[7].

- **Long-term sequelae:** Increased risk of metabolic syndrome and cardiovascular disorders in offspring^[7].

Prognosis and Recurrence Prevention

Maternal Recovery

Platelet recovery typically begins 24–48 hours post-delivery, normalizing by day 6^{[2] [6]}. Hepatic enzymes resolve within 3–5 days, though LDH may remain elevated for weeks^{[1] [2]}.

Recurrence Mitigation

- **Aspirin prophylaxis:** 81 mg daily from 12 weeks reduces preeclampsia recurrence by 17–24%^{[1] [7]}.
- **Calcium supplementation:** 1–1.5 g/day for low dietary intake populations^{[2] [4]}.
- **Surveillance:** Serial growth scans, uterine artery Doppler, and angiogenic marker monitoring (PIGF/sFlt-1 ratio)^{[3] [7]}.

Conclusion

HELLP syndrome remains a leading cause of maternal morbidity, demanding heightened clinical vigilance in pregnant women presenting with nonspecific viral-like symptoms. While incidence ranges from 0.05% to 0.9% in general pregnancies, its association with severe preeclampsia elevates risk twentyfold. Advances in biomarker discovery (e.g., sFlt-1/PIGF ratio) promise improved early diagnosis, while targeted anti-inflammatory therapies may soon augment current supportive management. Multidisciplinary care in tertiary centers, coupled with patient education on recurrence risks, remains pivotal to optimizing outcomes in this obstetric emergency.

✱

1. <https://www.aafp.org/pubs/afp/issues/1999/0901/p829.html>
2. <https://pmc.ncbi.nlm.nih.gov/articles/PMC2654858/>
3. <https://www.npeu.ox.ac.uk/ukoss/completed-surveillance/hellp-syndrome>
4. <https://www.mountsinai.org/health-library/diseases-conditions/hellp-syndrome>
5. <https://www.webmd.com/women/what-is-hellp-syndrome>
6. <https://my.clevelandclinic.org/health/diseases/21637-hellp-syndrome>
7. <https://www.yalemedicine.org/conditions/hellp-syndrome>
8. <https://medlineplus.gov/ency/article/000890.htm>